Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Hematology | Musculoskeletal | Family Medicine
Multiple Myeloma Clinical Trials
A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Anniston : Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Birmingham : University of Alabama at Birmingham
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Birmingham : Birmingham Hematology & Oncology Associates Llc
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Huntsville : Clearview Cancer Institute
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Huntsville : Clearview Cancer Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Huntsville : The Cancer Center of Huntsville
Connect® MM- The Multiple Myeloma Disease Registry
Mobile : Providence Cancer Center at Providence Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tuscaloosa : DCH Health System
Connect® MM- The Multiple Myeloma Disease Registry
Alaska
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Anchorage : Providence Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fairbanks : Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Arizona
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Phoenix : Arizona Oncology Associates
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Scottsdale :
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Scottsdale : Mayo Clinic Arizona
Dose-escalation Study of Oral CX-4945
Scottsdale : Mayo Clinic in Arizona
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Scottsdale : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Tucson : US Oncology - Arizona Oncology Associates - Rudasill
Connect® MM- The Multiple Myeloma Disease Registry
Tucson : Acrc/Arizona Clinical Research Center, Inc.
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Arkansas
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Fort Smith : St. Edward Mercy Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Hot Springs : Genesis Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Jonesboro : Clopton Clinic Hematology/Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Jonesboro : NEA Medical Clinic - East Matthews
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Little Rock : University of Arkansas Medical Sciences
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Little Rock : University of Arkansas for Medical Sciences
Compassionate Use Study of Carfilzomib
Little Rock : Little Rock Hematology Oncology Associates, PA
Connect® MM- The Multiple Myeloma Disease Registry
Little Rock : Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Little Rock : The University of Arkansas for Medical Sciences
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
Little Rock : University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy
UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma
Rogers : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
California
Duarte : City of Hope
A Phase I Study of ARRY-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (Protocol ARRAY-520-111)
Duarte : City of Hope
A Phase I/IIa Multi-Dose Escalation Study of BT062 in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed or Relapsed/Refractory Multiple Myeloma
Duarte : City of Hope
A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Oral AKT Inhibitor GSK2110183 Administered in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed/Refractory Multiple Myeloma
Duarte : City of Hope
An Open Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF-4539A in Patients with Relapsed or Refractory Multiple Myeloma
Duarte : City of Hope
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Duarte : City of Hope
BMT CTN 0702: A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma
Duarte : City of Hope
Correlating Organ Dose and Dose-Volume with Toxicities After Total Marrow Irradiation (TMI) Using Helical Tomotherapy in Patients Undergoing Hematopoetic Cell Transplantation (HCT)
Duarte : City of Hope
Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination with Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients with High Risk Multiple Myeloma
Duarte : City of Hope
SWOG S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Alhambra : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Anaheim : Pacific Cancer Medical Center Incorporated
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Anaheim : Pacific Cancer Medical Center, Inc.
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
Anaheim : Pacific Cancer Medical Center, Inc
Connect® MM- The Multiple Myeloma Disease Registry
Anaheim : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Bakersfield : Comprehensive Blood and Cancer Center
Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma
Berkeley : Alta Bates Summit Comprehensive Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Berkeley : Alta Bates Summit Comprehensive Cancer Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Burbank : Providence Saint Joseph Medical Center
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Campbell : Southbay Oncology Hematology Partners
Connect® MM- The Multiple Myeloma Disease Registry
Castro Valley : East Bay Radiation Oncology Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Castro Valley : Valley Medical Oncology Consultants - Castro Valley
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Concord : Cancer Care Center at John Muir Health - Concord Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Corona : Compassionate Cancer Care Medical Group (Corona)
Connect® MM- The Multiple Myeloma Disease Registry
Corona : Compassionate Cancer Care Medical Group Inc
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Corona : Compassionate Cancer Care Medical Group, Inc
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Duarte : City of Hope
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Duarte :
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Duarte : City of Hope Hospital
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Duarte : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Duarte : City of Hope Comprehensive Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Encinitas : Pacific Oncology and Hematology
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Escondido : Southwest Cancer Care
Connect® MM- The Multiple Myeloma Disease Registry
Fairfield : North Bay Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fountain Valley : Compassionate Cancer Care Medical Group (Fountain Valley)
Connect® MM- The Multiple Myeloma Disease Registry
Fremont : Valley Medical Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fresno : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Fullerton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Fullerton : Virginia K. Crosson Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Grass Valley : Sierra Nevada Cancer Center at Sierra Nevada Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenbrae : Marin Cancer Care, Inc
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
La Jolla : Moores UCSD Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
La Jolla : University of California, San Diego
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Lancaster : TORI - Antelope Valley Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
LaVerne :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Long Beach : Long Beach Memorial
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
Long Beach : Breastlink Medical Group, Incorporated at Long Beach Memorial Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Los Angeles : UCLA
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Los Angeles : USC/Norris Comprehensive Cancer Center
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
Los Angeles : USC/Norris Comprehensive Cancer Center and Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Los Angeles : Division Of Hematology & Oncology Ctr. For Health Sciences
Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy
Los Angeles : Ucla Department Of Medicine
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Los Angeles : UCLA Neuro-Oncology Program Updated
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Los Angeles : West Los Angeles VA Medical Center
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Martinez : Contra Costa Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Marysville : Tibotec Therapeutics - Division of Ortho Biotech Products, LP
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Merced : Mercy Cancer Center at Mercy Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Monterey : Monterey Bay Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Mountain View : El Camino Hospital Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Newport Beach : Michael J. Schlutz, M.D., Inc
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
Northridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Northridge : TORI - North Valley Hematology/Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Oakland : Hematology Oncology Associates
Connect® MM- The Multiple Myeloma Disease Registry
Oakland : Alta Bates Summit Medical Center - Summit Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oakland : Epic Care - Oakland
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oakland : Bay Area Breast Surgeons, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oakland : CCOP - Bay Area Tumor Institute
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oakland : Highland General Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oakland : Larry G Strieff MD Medical Corporation
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oakland : Tom K Lee, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Orange : Medical Oncology Care Associates
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Orange : St. Joseph Hospital Regional Cancer Center - Orange
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Orange : Medical Oncology Care Associates
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Oxnard : PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Palm Springs : Comprehensive Cancer Center at Desert Regional Medical Center
A Safety Study of Carfilzomib With Cyclophosphamide and Dexamethasone Prior to Autologous Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma
Palm Springs : Comprehensive Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Palo Alto : Stanford Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Pleasant Hill : Bay Area Cancer Research Group, LLC
Connect® MM- The Multiple Myeloma Disease Registry
Pleasant Hill : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Pleasanton : Valley Medical Oncology Consultants - Pleasanton
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Pomona : New Hope Cancer & Research Institute
Connect® MM- The Multiple Myeloma Disease Registry
Riverside : Campassionate Cancer Care Medical Group (Riverside)
Connect® MM- The Multiple Myeloma Disease Registry
Roseville : Capitol Hematology Oncology Medical Group - Sutter Roseville
Connect® MM- The Multiple Myeloma Disease Registry
Sacramento : University of California Davis Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Salinas : Pacific Cancer Care
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
San Diego : Sharp Clinical Oncology Research
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
San Diego : Sharp Clinical Oncology Research
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
San Francisco :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
San Francisco : University of California at San Francisco
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma
San Francisco : University of California at San Francisco Updated
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
San Pablo : Alta Bates Comprehensive Cancer Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
San Pablo :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
San Pablo : Doctors Medical Center - San Pablo Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Santa Barbara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Santa Barbara : Cancer Center of Santa Barbara
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
Santa Barbara : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Santa Maria : TORI - Central Coast Medical Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Santa Maria : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Santa Maria : Central Coast Medical Oncology
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Santa Maria : Central Coast Medical Oncology
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Santa Rosa : Redwood Regional Medical Group, Inc.
Connect® MM- The Multiple Myeloma Disease Registry
Stanford : Stanford University School of Medicine
Phase I/II Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Stockton : Stockton Hematology Oncology Medical Group, Inc.
Connect® MM- The Multiple Myeloma Disease Registry
Truckee : Tahoe Forest Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Walnut Creek : John Muir/Mt. Diablo Comprehensive Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
West Hollywood : James R Berenson, MD, Inc.
A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma
West Hollywood : James R. Berenson, MD, Inc.
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
West Hollywood : Berenson Oncology
A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma
West Hollywood : Institute for Myeloma and Bone Cancer Research
Connect® MM- The Multiple Myeloma Disease Registry
West Hollywood : James R. Berenson MD, Incorporated
Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma
West Hollywood : James R. Berenson M.D., Inc.
Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients
West Hollywood : James R. Berenson, MD, Inc.
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
West Hollywood : James R. berenson, M.D., Inc.
Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens
Colorado
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Aurora :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Aurora : US Oncology- Rocky Mountain Cancer Center-Aurora
Connect® MM- The Multiple Myeloma Disease Registry
Aurora : Aurora Presbyterian Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Boulder :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Boulder : US Oncology - Rocky Mountain Cancer Center-Boulder
Connect® MM- The Multiple Myeloma Disease Registry
Boulder : Boulder Community Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Colorado Springs :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Colorado Springs : US Oncology - Rocky Mountain Cancer Center-Colorado Springs
Connect® MM- The Multiple Myeloma Disease Registry
Colorado Springs : US Oncology- Rocky Mountain Cancer Center at the Pavillion
Connect® MM- The Multiple Myeloma Disease Registry
Colorado Springs : Memorial Hospital Cancer Center - Colorado Springs
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Colorado Springs : Penrose Cancer Center at Penrose Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Denver : RMCC
A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Denver :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Denver : Rocky Mountain Cancer Centers - Denver
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Denver : US Oncology - Rocky Mountain Cancer Center-Midtown
Connect® MM- The Multiple Myeloma Disease Registry
Denver : US Oncology - Rocky Mountain Cancer Center-Rose
Connect® MM- The Multiple Myeloma Disease Registry
Denver : Rocky Mountain Cancer Centers - Denver Midtown
Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma
Denver : Colorado Blood Cancer Institute
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Denver : CCOP - Colorado Cancer Research Program
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Denver : Porter Adventist Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Denver : St. Joseph Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Denver : Presbyterian - St. Luke's Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Denver : Rose Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Denver : St. Anthony Central Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Denver : Colorado Blood Cancer Institute
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function
Englewood : Swedish Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fort Collins : Front Range Cancer Specialists
Dose-escalation Study of Oral CX-4945
Fort Collins : Poudre Valley Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fort Collins : Front Range Cancer Specialists
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Grand Junction : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Grand Junction : TORI - St. Mary's Advanced Medical Pavilion
Connect® MM- The Multiple Myeloma Disease Registry
Grand Junction : St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greeley : North Colorado Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lakewood :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Lakewood : US Oncology - Rocky Mountain Cancer Center-Lakewood
Connect® MM- The Multiple Myeloma Disease Registry
Littleton :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Littleton : US Oncology - Rocky Mountain Cancer Center-Littleton
Connect® MM- The Multiple Myeloma Disease Registry
Littleton : Littleton Adventist Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lone Tree : US Oncology - Rocky Mountain Cancer Center-Sky Ridge
Connect® MM- The Multiple Myeloma Disease Registry
Lone Tree : Sky Ridge Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Longmont :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Longmont : US Oncology - Rocky Mountain Cancer Center-Longmont
Connect® MM- The Multiple Myeloma Disease Registry
Longmont : Hope Cancer Care Center at Longmont United Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Loveland : Front Range Cancer Specialists
Dose-escalation Study of Oral CX-4945
Loveland : McKee Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Parker :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Parker : US Oncology - Rocky Mountain Cancer Center-Parker
Connect® MM- The Multiple Myeloma Disease Registry
Parker : Parker Adventist Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Pueblo :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Pueblo : St. Mary - Corwin Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Thornton :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Thornton : US Oncology - Rocky Mountain Cancer Center-Thornton
Connect® MM- The Multiple Myeloma Disease Registry
Thornton : North Suburban Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wheat Ridge : Exempla Lutheran Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Connecticut
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Fairfield : Medical Specialists of Fairfield
Connect® MM- The Multiple Myeloma Disease Registry
Hartford : Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Manchester : Medical Oncology and Blood Disorders, LLP
Connect® MM- The Multiple Myeloma Disease Registry
New Britain : Hospital of Central Connecticut
Connect® MM- The Multiple Myeloma Disease Registry
New Haven : Yale University School Of Medicine
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
New Haven : Yale University School of Medicine
Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma
New Haven : Yale University
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
New Haven : Yale University School Of Medicine
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Stamford : Hematology Oncology, PC
Connect® MM- The Multiple Myeloma Disease Registry
Delaware
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Lewes : Tunnell Cancer Center at Beebe Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Newark : Delaware Clinical & Laboratory Physicians, PA
Connect® MM- The Multiple Myeloma Disease Registry
Newark : CCOP - Christiana Care Health Services
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
District of Columbia
Washington : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Washington : Georgetown Lombardi Comprehensive Cancer Center
Phase I Study of CS-7017 and Bexarotene
Washington : Washington Cancer Institute At Washington Hospital Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Florida
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Boynton Beach : Collaborative Research Group
Connect® MM- The Multiple Myeloma Disease Registry
Boynton Beach : Hematology Oncology Associates
Connect® MM- The Multiple Myeloma Disease Registry
Boynton Beach : University Cancer Institute
Connect® MM- The Multiple Myeloma Disease Registry
Boynton Beach : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Boynton Beach : Celgene Study Site
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Brooksville : Cancer Care Centers Of Florida
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Coral Springs : Flora Research Associates
Connect® MM- The Multiple Myeloma Disease Registry
Deerfield Beach : Archbold Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Deerfield Beach : Flora Research Associates
Connect® MM- The Multiple Myeloma Disease Registry
Fort Lauderdale : Broward General Medical Center Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fort Myers : Florida Cancer Specialists
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ft. Lauderdale : Broward Oncology Associates, PA
Connect® MM- The Multiple Myeloma Disease Registry
Gainesville : Florida Cancer Specialists & Research Institute
Connect® MM- The Multiple Myeloma Disease Registry
Hollywood : Memorial Cancer Institute
Connect® MM- The Multiple Myeloma Disease Registry
Hollywood : Celgene Study Site
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Hudson : US Oncology - Florida Cancer Institute - New Hope-Hudson
Connect® MM- The Multiple Myeloma Disease Registry
Jacksonville :
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Jacksonville : Mayo Clinic
BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma
Jacksonville : Integrated Community Oncology Network, LLC
Connect® MM- The Multiple Myeloma Disease Registry
Jacksonville : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Jacksonville : Integrated Community Oncology Network
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Jacksonville : Integrated Community Oncology Network
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Lake City : Cancer Care of North Florida
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Lakeland : Watson Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Lecanto : Cancer and Blood Disease Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Lecanto : Cancer & Blood Disease Center
Connect® MM- The Multiple Myeloma Disease Registry
Melbourne : Medical Associate of Brevard (MAB) Oncology/Hematology
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
New Port Richey : US Oncology - Florida Cancer Institute - New Hope-New Port Richey
Connect® MM- The Multiple Myeloma Disease Registry
New Port Richey : Pasco Hernando Oncology Associates (Kumar)
Connect® MM- The Multiple Myeloma Disease Registry
New Port Richey : Cancer Care Centers Of Florida
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ocala : Ocala Oncology Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Orlando : MD Anderson Orlando
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Pensacola : Sacred Heart Medical Oncology Group
Connect® MM- The Multiple Myeloma Disease Registry
Pensacola : Sacred Heart Cancer Center at Sacred Heart Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Pensacola : Sacred Heart Medical Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Rockledge : Cancer Care Centers of Brevard
Connect® MM- The Multiple Myeloma Disease Registry
St. Petersburg : Florida Cancer Specialists
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Tampa : H. Lee Moffitt Cancer Center & Research Institute
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Tampa : H. Lee Moffitt Cancer Center
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Tampa : Investigational Site Number 840001 Updated
Phase 1 SAR650984 Combination With Lenalidomide
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
Tampa : H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma
Tampa : Moffitt Cancer Center & Research Institute Updated
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The Villages : Florida Hospital Waterman-Lake County Oncology & Hematology
Connect® MM- The Multiple Myeloma Disease Registry
Titusville : Space Coast Medical Associates
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
West Palm Beach : Palm Beach Cancer Institute
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
West Palm Beach : Palm Beach Cancer Institute
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
West Palm Beach : Palm Beach Cancer Institute
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Weston : Cleveland Clinic Florida
Connect® MM- The Multiple Myeloma Disease Registry
Georgia
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Albany : Phoebe Putney Memorial Hospital
Connect® MM- The Multiple Myeloma Disease Registry
Atlanta : Emory
A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Atlanta : Emory University Winship Cancer Institute
A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Atlanta : Winship Cancer Institute of Emory University
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Atlanta : Emory University, Winship Cancer Institute
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Atlanta : Emory University, Winship Cancer Institute
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Atlanta : Georgia Cancer Specialists
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Atlanta : Emory University
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Atlanta : Georgia Cancer Specialists
Connect® MM- The Multiple Myeloma Disease Registry
Atlanta : Peachtree Hematology-Oncology Consultants
Connect® MM- The Multiple Myeloma Disease Registry
Atlanta : Emory University Winship Cancer Institute
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Atlanta : Emory University Winship Cancer
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Atlanta : Winship Cancer Institute, Emory University
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Atlanta : Winship Cancer Institute, Emory University
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
Atlanta : CCOP - Atlanta Regional
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Atlanta : Piedmont Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Atlanta : Saint Joseph's Hospital of Atlanta
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Atlanta : Northside Hospital Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Atlanta : Emory University Winship Cancer Institute
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Atlanta : Winship Cancer Institute, Emory University
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Atlanta : Emory University
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Atlanta : Emory University
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Augusta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Austell : WellStar Cobb Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Columbus : John B. Amos Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Decatur : Charles B. Eberhart Cancer Center at DeKalb Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fayetteville : Piedmont Fayette Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Gainesville : Northeast Georgia Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lawrenceville : Gwinnett Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Marietta : Northwest Georgia Oncology Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Marietta : Kennestone Cancer Center at Wellstar Kennestone Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Riverdale : Southern Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Rome : Harbin Clinic Cancer Center - Medical Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Savannah : Summit Cancer Care
Connect® MM- The Multiple Myeloma Disease Registry
Savannah : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Savannah : Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Valdosta : Pearlman Comprehensive Cancer Center at South Georgia Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Hawaii
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Aiea : Kapiolani Medical Center at Pali Momi
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : Straub Clinic and Hospital
Connect® MM- The Multiple Myeloma Disease Registry
Honolulu : Cancer Research Center of Hawaii
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : Queen's Cancer Institute at Queen's Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : Tripler Army Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : Hawaii Medical Center - East
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : Kapiolani Medical Center for Women and Children
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : OnCare Hawaii, Incorporated - Kuakini
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : OnCare Hawaii, Incorporated - Lusitana
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Honolulu : Straub Clinic and Hospital, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lihue : Kauai Medical Clinic
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wailuku : Maui Memorial Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wailuku : Pacific Cancer Institute - Maui
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Idaho
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Boise : Mountain States Tumor Institute at St. Luke's Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Boise : Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fruitland : Saint Luke's Mountain States Tumor Institute - Fruitland
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lewiston : St. Joseph Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Meridian : Mountain States Tumor Institute - Meridian
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Nampa : Saint Luke's Mountain States Tumor Institute
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Twin Falls : Mountain States Tumor Institute at St. Luke's
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Illinois
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Arlington Heights : Cancer Care & Hematology Specialists of Chicagoland, PC
Connect® MM- The Multiple Myeloma Disease Registry
Aurora : Rush-Copley Cancer Care Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Carbondale : Memorial Hospital of Carbondale
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Chicago : John H. Stroger Jr. Hospital of Cook County
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Chicago : University of Chicago
A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Chicago :
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Chicago :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Chicago : Rush University Medical Center
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Chicago : University Of Chicago Medical Center
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Chicago : John H. Stroger, Jr. Hospital of Cook County
Connect® MM- The Multiple Myeloma Disease Registry
Chicago : Rush University Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Chicago : Univeristy of Chicago Medical Center, Section of Hematology/Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Chicago : University of IL at Chicago
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Chicago : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Chicago : University of Chicago, School of Medicine
Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Chicago : The University Of Chicago
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Chicago : John H. Stroger, Jr. Hospital of Cook County
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Chicago : Louis A. Weiss Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Chicago : The University of Chicago
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Chicago : University Of Chicago Medical Center
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Decatur : Decatur Memorial Hospital Cancer Care Institute
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Decatur : Cancer Care Specialists Of Central Illinois
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Elgin : Sherman Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elmhurst : Elmhurst Memorial Hospital
Connect® MM- The Multiple Myeloma Disease Registry
Evanston : Northshore University Health System
Connect® MM- The Multiple Myeloma Disease Registry
Evanston : Evanston Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Galesburg : Medical and Surgical Specialists
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Geneva : Delnor Hospital - Geneva
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Harvey : Ingalls Cancer Research Center
Connect® MM- The Multiple Myeloma Disease Registry
Hines : Veterans Affairs Medical Center - Hines
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Hines : Edward Hines Jr VA Hospital
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Joliet : Joliet Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Joliet : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Maywood : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Maywood : Cardinal Bernardin Cancer Center at Loyola University Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Maywood : Loyola University Medical Center, Cardinal Bernardin Cancer Center
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Moline : Medical Arts Associates, Ltd
Connect® MM- The Multiple Myeloma Disease Registry
Moline :
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Moline : Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mount Vernon : Good Samaritan Regional Health Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Niles :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Niles : Oncology Specialists, S.C.
Connect® MM- The Multiple Myeloma Disease Registry
Niles : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Park Ridge : Oncology Specialists, S.C.
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Peoria : Illinois Cancer Care
Connect® MM- The Multiple Myeloma Disease Registry
River Forest : West Suburban Center for Cancer Care
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Skokie : Orchard Research
Connect® MM- The Multiple Myeloma Disease Registry
Skokie : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Springfield : Regional Cancer Center at Memorial Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Urbana : Carle Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Urbana : CCOP - Carle Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Urbana : Carle Cancer Center
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Warrenville : Central Dupage Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Winfield :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Zion : Cancer Centers of America
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Indiana
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Anderson : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Beech Grove : Indiana Blood and Marrow Transplant, LLC
Connect® MM- The Multiple Myeloma Disease Registry
Beech Grove : St. Francis Cancer Research
Connect® MM- The Multiple Myeloma Disease Registry
Beech Grove : St. Francis Hospital and Health Centers - Beech Grove Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elkhart : Elkhart Clinic, LLC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elkhart : Elkhart General Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elkhart : Michiana Hematology-Oncology, PC - Elkhart
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fort Wayne : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Goshen : IU Health Goshen Hospital
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Goshen : Center for Cancer Care @ Goshen Health Systems
Connect® MM- The Multiple Myeloma Disease Registry
Indianapolis : Indiana University Simon Cancer Center
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Indianapolis : IU Simon Cancer Center
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Indianapolis : Indiana University Melvin and Bren Simon Cancer Center
Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)
Indianapolis : Indiana University Melvin and Bren Simon Cancer Center
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Indianapolis : IU Health Central Indiana Cancer Centers
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Indianapolis : Community Regional Cancer Center
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Indianapolis : Investigative Clinical Research Of Indiana, Llc
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Indianapolis : Indiana University Simon Cancer Center IU Simon Cancer Center Clinical Research Office, RT 380
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Indianapolis : Indiana University Cancer Center Clinical Research Office
Connect® MM- The Multiple Myeloma Disease Registry
Indianapolis : IU Simon Cancer Center Updated
Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
Indianapolis : Hematology-Oncology of Indiana, PC
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Indianapolis : Investigative Clinical Research Of Indiana, Llc
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Indianapolis : Investigative Clinical Research Of Indiana, Llc
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Indianapolis : Franciscan St. Francis Health
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Kokomo : Howard Community Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
La Porte : Center for Cancer Therapy at LaPorte Hospital and Health Services
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Michigan City : Saint Anthony Memorial Health Centers
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mishawaka : Michiana Hematology Oncology, P.C.
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Mishawaka : Saint Joseph Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mishawaka : Michiana Hematology-Oncology, PC - South Bend
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Munster : Cancer Research-Munster
Connect® MM- The Multiple Myeloma Disease Registry
New Albany : Cancer Care Center Inc.
Connect® MM- The Multiple Myeloma Disease Registry
Newburgh : Oncology Hematology Associates of SW IN
Connect® MM- The Multiple Myeloma Disease Registry
Plymouth : Michiana Hematology Oncology PC - Plymouth
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Richmond : Reid Hospital & Health Care Services
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
South Bend : Northern Indiana Cancer Research Consortium
Connect® MM- The Multiple Myeloma Disease Registry
South Bend : CCOP - Northern Indiana CR Consortium
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
South Bend : Memorial Hospital of South Bend
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Westville : Michiana Hematology Oncology PC - La Porte
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Iowa
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Ames : McFarland Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Ames : McFarland Clinic
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Ames : McFarland Clinic, PC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bettendorf : Hematology Oncology Associates of the Quad Cities
Connect® MM- The Multiple Myeloma Disease Registry
Bettendorf :
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Cedar Rapids : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Cedar Rapids : Iowa Blood and Cancer Care of PCI
Connect® MM- The Multiple Myeloma Disease Registry
Cedar Rapids : Cedar Rapids Oncology Associates
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Cedar Rapids : Mercy Regional Cancer Center at Mercy Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Clive : Medical Oncology and Hematology Associates - West Des Moines
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Davenport : Genesis Regional Cancer Center at Genesis Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Des Moines : CCOP - Iowa Oncology Research Association
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Des Moines : John Stoddard Cancer Center at Iowa Methodist Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Des Moines : Mercy Cancer Center at Mercy Medical Center - Des Moines
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Des Moines : John Stoddard Cancer Center at Iowa Lutheran Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Des Moines : Medical Oncology and Hematology Associates at John Stoddard Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Des Moines : Medical Oncology and Hematology Associates at Mercy Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Iowa City : University of Iowa Hospitals
A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Iowa City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Iowa City : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Iowa City : University Of Iowa Hospitals And Clinics
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Mason City : Mercy Cancer Center at Mercy Medical Center - North Iowa
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Sioux City : Siouxland Hematology-Oncology Associates, LLP
Connect® MM- The Multiple Myeloma Disease Registry
Sioux City : Siouxland Hematology Oncology Associates
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Sioux City : Mercy Medical Center - Sioux City
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Sioux City : Siouxland Hematology-Oncology Associates, LLP
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Sioux City : St. Luke's Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Waterloo : Cedar Valley Medical Specialists
Connect® MM- The Multiple Myeloma Disease Registry
Waterloo : Covenant Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Kansas
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Chanute : Cancer Center of Kansas, PA - Chanute
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Dodge City : Cancer Center of Kansas, PA - Dodge City
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
El Dorado : Cancer Center of Kansas, PA - El Dorado
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fairway : University of Kansas Medical Center
Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Fort Scott : Cancer Center of Kansas - Fort Scott
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Independence : Cancer Center of Kansas-Independence
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kingman : Cancer Center of Kansas, PA - Kingman
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lawrence : Lawrence Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Liberal : Cancer Center of Kansas, PA - Liberal
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
McPherson : Cancer Center of Kansas, PA - McPherson
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Newton : Cancer Center of Kansas, PA - Newton
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Overland Park : Menorah Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Overland Park : Saint Luke's Hospital - South
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Parsons : Cancer Center of Kansas, PA - Parsons
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Prairie Village : CCOP - Kansas City
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Prairie Village : Kansas City CCOP
S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
Pratt : Cancer Center of Kansas, PA - Pratt
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Salina : Cancer Center of Kansas, PA - Salina
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Salina : Tammy Walker Cancer Center at Salina Regional Health Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Topeka : Cotton-O'Neil Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wellington : Cancer Center of Kansas, PA - Wellington
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wichita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Wichita : Cancer Center of Kansas, PA
Connect® MM- The Multiple Myeloma Disease Registry
Wichita : Associates in Womens Health, PA - North Review
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wichita : Cancer Center of Kansas, PA - Medical Arts Tower
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wichita : CCOP - Wichita
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wichita : Cancer Center of Kansas, PA - Wichita
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wichita : Via Christi Cancer Center at Via Christi Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Winfield : Cancer Center of Kansas, PA - Winfield
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kentucky
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Ashland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Hazard : Kentucky Cancer Clinic
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Hazard : Kentucky Cancer Clinic
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Louisville : Baptist Hospital East
Connect® MM- The Multiple Myeloma Disease Registry
Paducah : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Louisiana
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Baton Rouge : Mary Bird Perkins Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Baton Rouge : Ochsner Health Center - Bluebonnet
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Covington : Ochsner Health Center - Covington
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lafayette : Cancer Center Of Acadiana At Lafayette General
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Lafayette : Cancer Center Of Acadiana
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Monroe : Louisiana State University Health Sciences Center - Monroe
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
New Orleans : Ochsner Cancer Institute at Ochsner Clinic Foundation
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
New Orleans : CCOP - Ochsner
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Shreveport : Feist-Weiller Cancer Center at Louisiana State University Health Sciences
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Shreveport : Highland Clinic
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Maine
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Scarborough : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Maryland
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Baltimore : Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission
Baltimore :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Baltimore : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Baltimore : Sidney Kimmel Cancer Center Johns Hopkins Hospital
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
Baltimore : University of Maryland Medical Center - M & S Greenebaum Cancer Center
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
Baltimore : University of Maryland Greenebaum Cancer Center
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Baltimore : Greater Baltimore Medical Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Baltimore : Harry & Jeanette Weinberg Cancer Institute
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Baltimore : Greater Baltimore Medical Center
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Baltimore : Johns Hopkins University
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Bethesda : Center for Cancer and Blood Disorders
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Bethesda :
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Bethesda : Center for Cancer & Blood Disorders, PC
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike
Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
Bethesda : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike
Lenalidomide Maintenance Therapy for Multiple Myeloma
Bethesda : Center for Cancer and Blood Disorders
Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma
Bethesda : Center for Cancer and Blood Disorders
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Bethesda : Center for Cancer and Blood Disorders
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Bethesda : National Capital Clinical Research Consortium
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
Bethesda : Center for Cancer and Blood Disorders
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Columbia :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Elkton MD : Union Hospital of Cecil County
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Rockville :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Rockville :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Rockville : Associates in Oncology/Hematology, P.C.
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Westminster : Alliance Hematology Oncology, PA
Connect® MM- The Multiple Myeloma Disease Registry
Westminster : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Massachusetts
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Boston : Dana Farber Cancer Institute
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Boston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Boston : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Boston : Dana-Farber Cancer Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Boston : Dana Farber Cancer Institute
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Boston : Dana Farber Cancer Institute
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Boston : Dana-Farber Cancer Institute
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Boston : Dana-Farber Cancer Institute
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Boston : Dana-Farber Cancer Institute
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Boston : Beth Israel Deaconess Medical Center
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Boston : Dana Faber Cancer Institute
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Boston : Massachusetts General Hospital
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Boston : Dana-Farber Cancer Institute
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Boston : Massachusetts General Hospital
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Boston : Dana Farber Cancer Institute
Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Boston : Massachusetts General Hospital
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
Boston : Dana-Farber Cancer Institute
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Boston : Dana-Farber Cancer Institute
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Boston : Beth Israel Deaconess Medical Center
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Boston : Massachusetts General Hospital
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Boston : Beth Israel Deaconess Medical Center
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Boston : Massachusetts General Hospital
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Boston : Dana-Farber Cancer Institute
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Boston : Dana-Farber Cancer Institute
Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy
Boston : Dana Farber Cancer Institute
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Boston : Tufts Medical Center
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Boston : Massachusetts General Hospital
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Boston : Massachusetts General Hospital
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
Boston : Dana Farber Cancer Institute
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Boston : Dana Farber Cancer Institute
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Boston : Massachusetts General Hospital
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Boston : Beth Israel Deaconess Medical Center
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Hyannis : Capecod Hospital/Davenport Mugar Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Jamaica Plain : VA Boston Healthcare System
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Methuen : Caritas Holy Family Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Worcester : Fallon Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Worcester : University of Massachusetts
Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Worcester : Reliant Medical Group, Inc
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Michigan
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Adrian : Hickman Cancer Center at Bixby Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Ann Arbor : University of Michigan Comprehensive Cancer Center Main Office
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Ann Arbor : Michigan Cancer Research Consortium and Oncology Research- St. Joseph Mercy Hospital - Ann Arbor
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Ann Arbor : University of Michigan
Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Ann Arbor : University Of Michigan
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ann Arbor : CCOP - Michigan Cancer Research Consortium
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Ann Arbor : University of Michigan Comprehensive Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Ann Arbor : Saint Joseph Mercy Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Battle Creek : Battle Creek Health System Cancer Care Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bay City : Michigan State University/Bay Regional Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Bay City : Bay Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Big Rapids : Mecosta County Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Dearborn : Oakwood Cancer Center at Oakwood Hospital and Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Detroit : Karmanos Cancer Institute
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Detroit : Karmanos Cancer Institute
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Detroit :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Detroit : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Detroit : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Detroit : Henry Ford Health System
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Detroit : Barbara Ann Karmanos Cancer Institute
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Detroit : Josephine Ford Cancer Center at Henry Ford Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Escanaba : Green Bay Oncology, Limited - Escanaba
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Flint : Genesys Hurley Cancer Institute
Connect® MM- The Multiple Myeloma Disease Registry
Flint : Michigan State University/McLaren Regional Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Flint : Genesys Hurley Cancer Institute
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Flint : Hurley Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Flint : McLaren Cancer Institute
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Flint : Singh and Arora Hematology Oncology, PC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Grand Rapids : Grand Rapids Clinical Oncology Program
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Grand Rapids : Butterworth Hospital at Spectrum Health
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Grand Rapids : CCOP - Grand Rapids
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Grand Rapids : Lacks Cancer Center at Saint Mary's Health Care
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Grosse Pointe Woods : Van Elslander Cancer Center at St. John Hospital and Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Iron Mountain : Dickinson County Healthcare System
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Jackson : Foote Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kalamazoo : West Michigan Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Kalamazoo : Borgess Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kalamazoo : Bronson Methodist Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kalamazoo : West Michigan Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lansing : Michigan State University/Breslin Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Lansing : Breslin Cancer Center at Ingham Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lansing : Sparrow Regional Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lapeer : Michigan State University/Lapeer Regional Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Lapeer : Great Lakes Cancer Institute - Lapeer Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Livonia : St. Mary Mercy Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Monroe : Community Cancer Center of Monroe
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Monroe : Mercy Memorial Hospital - Monroe
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mount Clemens : Michigan State University/Mount Clemens Regional Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Mount Clemens : Clemens Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Muskegon : Mercy General Health Partners
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Novi : Newland Medical Associates
Connect® MM- The Multiple Myeloma Disease Registry
Owosso : Michigan State University/Memorial Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Petoskey : Northern Michigan Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Pontiac : St. Joseph Mercy Oakland
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Port Huron : Mercy Regional Cancer Center at Mercy Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Reed City : Spectrum Health Reed City Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Royal Oak : William Beaumont Hospital - Royal Oak Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saginaw : Seton Cancer Institute at Saint Mary's - Saginaw
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saint Joseph : Lakeland Regional Cancer Care Center - St. Joseph
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saint Joseph : Lakeside Cancer Specialists, PLLC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Southfield : Newland Medical Associates
Connect® MM- The Multiple Myeloma Disease Registry
Southfield : Providence Cancer Institute at Providence Hospital - Southfield Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Traverse City : Munson Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Warren : St. John Macomb Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wyoming : Metro Health Cancer Care
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Minnesota
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Brainerd : St. Joseph's Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Burnsville : Fairview Ridges Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Coon Rapids : Mercy and Unity Cancer Center at Mercy Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Duluth : Duluth Clinic Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Duluth : CCOP - Duluth
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Duluth : Duluth Clinic Cancer Center - Duluth
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Duluth : Miller - Dwan Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Edina : Fairview Southdale Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fridley : Mercy and Unity Cancer Center at Unity Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Hutchinson : Hutchinson Area Health Care
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Maplewood : Minnesota Oncology - Maplewood
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Maplewood : HealthEast Cancer Care at St. John's Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Minneapolis : Minnesota Oncology Hematology P.A.
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Minneapolis : Hennepin County Medical Center - Minneapolis
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Minneapolis : Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Minneapolis : University of Minnesota: Masonic Cancer Center, BMT Clinic, and Fairview Medical Center
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
New Ulm : New Ulm Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Robbinsdale : Humphrey Cancer Center at North Memorial Outpatient Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Rochester : Mayo Clinic
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Rochester : Mayo Clinic - Rochester Mayo 3
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Rochester : Mayo Clinic
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Rochester : The Mayo Clinic
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
Saint Louis Park : CCOP - Metro-Minnesota
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saint Louis Park : Park Nicollet Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saint Paul : United Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Shakopee : St. Francis Cancer Center at St. Francis Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
St. Louis Park : Park Nicollet Institute - Louisiana Ave.
Connect® MM- The Multiple Myeloma Disease Registry
St. Louis Park : Metro MN CCOP
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
St. Paul : Regions Hospital Cancer Care Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Stillwater : Lakeview Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Waconia : Ridgeview Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Willmar : Willmar Cancer Center at Rice Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Woodbury : Minnesota Oncology - Woodbury
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mississippi
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Jackson : Jackson Oncology Associates
Connect® MM- The Multiple Myeloma Disease Registry
Jackson : University of Mississippi Cancer Clinic
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Jackson : Veterans Affairs Medical Center - Jackson
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Pascagoula : Regional Cancer Center at Singing River Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Missouri
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Cape Girardeau : Saint Francis Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Cape Girardeau : Southeast Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Chesterfield : St. Louis Cancer Care, LLP
Connect® MM- The Multiple Myeloma Disease Registry
Jefferson City : Capitol Comprehensive Cancer Care Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Jefferson City : Columbia Comprehensive Cancer Care Clinic
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Jefferson City : Goldschmidt Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kansas City : Kansas City Cancer Center
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Kansas City : Research Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kansas City : Heartland Hematology Oncology Associates, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kansas City : North Kansas City Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kansas City : Saint Luke's Cancer Institute at Saint Luke's Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kansas City : Veterans Affairs Medical Center - Kansas City
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kansas City : Kansas City VA Medical Center
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Lee's Summit : Saint Luke's East - Lee's Summit
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Liberty : Parvin Radiation Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saint Joseph : Saint Joseph Oncology, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saint Joseph : Heartland Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saint Louis : Midwest Hematology Oncology Group, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saint Louis : Missouri Baptist Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saint Louis : CCOP - St. Louis-Cape Girardeau
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saint Louis : Christian Hospital Northeast Cancer Care Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saint Louis : David C. Pratt Cancer Center at St. John's Mercy
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saint Louis : Saint Louis University Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Springfield : St. John's Medical Research Institute
Connect® MM- The Multiple Myeloma Disease Registry
Springfield : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Springfield : Mercy Medical Research Institute
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Springfield : Mercy Medical Research Institute
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
St Louis : Washington University
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
St Louis : Investigational Site Number 840002 Updated
Phase 1 SAR650984 Combination With Lenalidomide
St Louis : Washington University School of Medicine
Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
St. Joseph : St. Joseph Oncology
Connect® MM- The Multiple Myeloma Disease Registry
St. Louis : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
St. Louis : Washington University School of Medicine
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
St. Louis : Hematology Oncology Consultants, Inc
Connect® MM- The Multiple Myeloma Disease Registry
St. Louis : St. John's Mercy Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
St. Louis : University Hematology Oncology, Inc.
Connect® MM- The Multiple Myeloma Disease Registry
St. Louis : Washington University in St. Louis, Division of Oncology, Section of Bone Marrow Transplantation & Leukemia
Connect® MM- The Multiple Myeloma Disease Registry
St. Louis : Washington University School of Medicine Division of Oncology
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
St. Louis : Washington University School Of Medicine
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
St. Louis : Washington University School Of Medicine
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
St. Louis : Washington University School of Medicine
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Montana
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Billings : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Billings : Billings Clinic - Downtown
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Billings : St. Vincent Healthcare Cancer Care Services
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Billings : CCOP - Montana Cancer Consortium
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Billings : Hematology-Oncology Centers of the Northern Rockies - Billings
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bozeman : Bozeman Deaconess Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Butte : St. James Healthcare Cancer Care
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Great Falls : Sletten Cancer Institute at Benefis Healthcare
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Great Falls : Big Sky Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Helena : St. Peter's Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kalispell : Kalispell Medical Oncology at KRMC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kalispell : Kalispell Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Missoula : Montana Cancer Institute Foundation
Connect® MM- The Multiple Myeloma Disease Registry
Missoula : Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Missoula : Montana Cancer Specialists at Montana Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Nebraska
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Kearney : Good Samaritan Cancer Center at Good Samaritan Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lincoln : Nebraska Hematology Oncology, PC
Connect® MM- The Multiple Myeloma Disease Registry
Lincoln : Southeast Nebraska Hematology & Oncology Consultants, PC
Connect® MM- The Multiple Myeloma Disease Registry
Lincoln : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Lincoln : Cancer Resource Center - Lincoln
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Omaha : University of Nebraska Medical Center
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Omaha : Missouri Valley Cancer Consortium
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Omaha : CCOP - Missouri Valley Cancer Consortium
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Omaha : Immanuel Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Omaha : Alegant Health Cancer Center at Bergan Mercy Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Omaha : Creighton University Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Omaha : Lakeside Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Nevada
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Henderson : TORI - Comprehensive Cancer Centers of NV
Connect® MM- The Multiple Myeloma Disease Registry
Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Las Vegas : Southern Nevada Cancer Research Foundation
Connect® MM- The Multiple Myeloma Disease Registry
Las Vegas : University Medical Center of Southern Nevada
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Las Vegas : CCOP - Nevada Cancer Research Foundation
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Las Vegas : Nevada Cancer Institute
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Reno : VA Sierra Nevada Healthcare System
Connect® MM- The Multiple Myeloma Disease Registry
New Hampshire
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Lebanon : Dartmouth Hitchcock Medical Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Lebanon : Dartmouth Hitchcock Medical Center
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Portsmouth : Portsmouth Regional Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
New Jersey
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Belleville : Essex Oncology of North Jersey, PA
Connect® MM- The Multiple Myeloma Disease Registry
Cherry Hill : The Center for Cancer and Hematologic Disease
Connect® MM- The Multiple Myeloma Disease Registry
Englewood : Drs. Forte, Schleider, Attas & Condemi, PA
Connect® MM- The Multiple Myeloma Disease Registry
Hackensack : HUMC
A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Hackensack : Hackensack University Medical Center
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Hackensack : Hackensack University Medical Center
BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma
Hackensack : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Hackensack : John Theurer Cancer Center at Hackensack University Medical Center
Escalating Doses Thalidomide+Bortezomib+HIgh Dose Melphalan for Auto PBSC Transplant in Patients With Multiple Myeloma
Hackensack : Hackensack University Medical Center
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Hackensack : John Theurer Cancer Center at Hackensack University
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Hackensack : Hackensack University Medical Center
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Hackensack : Hackensack University Medical Center
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Hackensack : Hackensack University Medical Center
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
Hackensack : John Theurer Cancer Center
Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy
Hackensack : John Theurer Cancer Center-Hackensack University Medical Center
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function
Hackensack : John Theurer Cancer Center at Hackensack University Updated
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Hackensack : John Theurer Cancer Center - Hackensack University
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Morristown :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Morristown : Hematology-Oncology Associates of Northern NJ dba Carol G. Simon
Connect® MM- The Multiple Myeloma Disease Registry
Morristown : Celgene Study Site
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Newark : UMDNJ University Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Somerville : Steeplechase Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Voorhees : Cancer Institute of New Jersey at Cooper - Voorhees
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
New Mexico
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Albuquerque : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Albuquerque : University of New Mexico Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Albuquerque : Hematology Oncology Associates, PC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
New York
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
Phase 2 Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell (PBSC) Transplant in Patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma, or Multiple Myeloma Undergoing Limited Re-infusion of CD34+ Cells
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Albany : New York Oncology Hematology, P.C.
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Albany : US Oncology - Albany Medical Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Albany : US Oncology - New York Oncology Hematology, PC-Albany
Connect® MM- The Multiple Myeloma Disease Registry
Amsterdam : US Oncology - Amsterdam Community Cancer Program
Connect® MM- The Multiple Myeloma Disease Registry
Bronx : Bronx River Medical Associates
Connect® MM- The Multiple Myeloma Disease Registry
Bronx : Eastchester Center for Cancer Care
Connect® MM- The Multiple Myeloma Disease Registry
Bronx : Montefiore Medical Center
Study of Intravenous Busulfan in Combination With Melphalan and Bortezomib in Patients With Multiple Myeloma
Buffalo : Jonah Cancer Care Center & ECMC
Connect® MM- The Multiple Myeloma Disease Registry
Buffalo : Roswell Park Cancer Institute
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
East Syracuse : CCOP - Hematology-Oncology Associates of Central New York
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elmira : Falck Cancer Center at Arnot Ogden Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Great Neck :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Hudson : US Oncology - Cavell Cancer Treatment Program
Connect® MM- The Multiple Myeloma Disease Registry
Johnson City : Broome Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Lake Success : Arena Oncology Associates, PC
Connect® MM- The Multiple Myeloma Disease Registry
Latham : US Oncology - New York Oncology Hematology, PC-Latham
Connect® MM- The Multiple Myeloma Disease Registry
Long Island : Stony Brook
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
New Hyde Park : Long Island Jewish medical Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
New York : Columbia University Medical Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
New York : Weill Medical College of Cornell University
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
New York : Columbia University
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
New York : Mount Sinai Medical Center
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
New York :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
New York : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
New York : NYU Cancer Institute
A Study to Evaluate the Use of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Multiple Myeloma
New York : Memorial Sloan-Kettering Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
New York : Weill Medical College of Cornell
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
New York : Memorial Sloan Kettering Cancer Center
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
New York : New York University Langone Medical Center
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
New York : Memorial Sloan-Kettering Cancer Center
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
New York : Memorial Sloan-Kettering Cancer Center
Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
New York : Memorial Sloane Kettering Cancer Center
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
New York : Weill Cornell Medicial College
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
New York : Memorial Sloan-Kettering Cancer Centre
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
New York : Weill Cornell Medical College
Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
New York : Memorial Sloan-Kettering Cancer Center
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
New York : Mount Sinai School of Medicine
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
New York : Memorial Sloan-Kettering Cancer Center
Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
New York : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
New York :
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
New York : Weill Medical College of Cornell University
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
New York : Mount Sinai School of Medicine
Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)
New York : St. Luke'S Roosevelt Hospital Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
New York : St. Luke'S-Roosevelt Hospital Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
New York : Mount Sinai School of Medicine, The Tisch Cancer Institute
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
New York : Memorial Sloan Kettering Cancer Center
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
New York : The Mount Sinai School of Medicine
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
New York : Memorial Sloan Kettering Cancer Ctr
Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy
New York : Mt. Sinai Medical Center
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
New York : Weill Cornell Medical College
Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
New York : Mount Sinai School of Medicine
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
New York : Memorial Sloan Kettering Cancer Center
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
New York : NYU Cancer Institute Updated
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
New York : Weill Cornell Medical College
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
New York City : Cornell
A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Rexford : US Oncology - New York Oncology Hematology, PC-Rexford
Connect® MM- The Multiple Myeloma Disease Registry
Rochester : James P. Wilmot Cancer Center at University of Rochester Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Stony Brook : Stony Brook University Hospital
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
Stony Brook : Stony Brook University Medical Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Syracuse : SUNY Upstate Medical University - Adult Program
Connect® MM- The Multiple Myeloma Disease Registry
Troy : US Oncology - Troy Cancer Treatment Program
Connect® MM- The Multiple Myeloma Disease Registry
North Carolina
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Asheville : Mission Hospitals - Memorial Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Cary : US Oncology - Cancer Centers of North Carolina - Cary
Connect® MM- The Multiple Myeloma Disease Registry
Chapel Hill : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Chapel Hill : UNC Lineberger Comprehensive Cancer Center
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Chapel Hill : University of North Carolina at Chapel Hill
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Chapel Hill : UNC Lineberger Comprehensive Cancer Center
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
Charlotte : Carolinas Medical Center
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Charlotte : Mecklenburg Medical Group
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Charlotte : Presbyterian Cancer Center at Presbyterian Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Durham : Duke University Medical Center
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Durham : DUMC Division of Cellular Therapy/ABMT
Connect® MM- The Multiple Myeloma Disease Registry
Durham : Duke University
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Durham : Duke University Medical Center
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Durham : Duke University Medical Center
Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
Fayetteville : Blood and Cancer Clinic
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Fayetteville : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Goldsboro : Southeastern Medical Oncology Center
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Goldsboro : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Goldsboro : Wayne Memorial Hospital, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Hendersonville : Pardee Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Hickory : Carolina Oncology Specialists, PA
Connect® MM- The Multiple Myeloma Disease Registry
High Point : Emerywood Hematology/Oncology
Connect® MM- The Multiple Myeloma Disease Registry
High Point : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Pinehurst : FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Raleigh : US Oncology - Cancer Centers of North Carolina - Falls
Connect® MM- The Multiple Myeloma Disease Registry
Rutherfordton : Rutherford Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Statesville : Iredell Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Winston-Salem : Piedmont Hematology Oncology Associates, Pa
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Winston-Salem : Forsyth Regional Cancer Center at Forsyth Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
North Dakota
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Bismarck : Mid Dakota Clinic, Pc
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Bismarck : Legacy Pharma Research
Connect® MM- The Multiple Myeloma Disease Registry
Bismarck : Med Center One
Connect® MM- The Multiple Myeloma Disease Registry
Bismarck : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Fargo :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Fargo : Roger Maris Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Ohio
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Akron : Summa Health System - Cancer Research Office
Connect® MM- The Multiple Myeloma Disease Registry
Akron : McDowell Cancer Center at Akron General Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bowling Green : Wood County Oncology Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Canton : Gabrail Cancer Center Research
Connect® MM- The Multiple Myeloma Disease Registry
Canton : Gabrail Cancer Center Research
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Canton : Celgene Study Site
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Chillicothe : Adena Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Cincinnati : Christ Hospital Cancer Center
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Cincinnati : Oncology Hematology Care Inc.
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Cincinnati : Charles M. Barrett Cancer Center at University Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Cleveland : University Hospitals Seidman Cancer Center
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Cleveland : University Hospitals Case Medical Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Cleveland : Cleveland VA Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Cleveland : Cleveland Clinic
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Cleveland : Case Western Reserve University, University Hospitals of Cleveland
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cleveland : Cleveland Clinic, Taussig Cancer Institute
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cleveland : Cleveland Clinic-Taussig Cancer Center
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function
Columbus : OSU
A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Columbus : The Ohio State University Medical Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Columbus : Mid Ohio Oncology/Hematology, Inc
Connect® MM- The Multiple Myeloma Disease Registry
Columbus : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Columbus : Benson, Md, Don
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Columbus : CCOP - Columbus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Columbus : Grant Medical Center Cancer Care
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Columbus : Riverside Methodist Hospital Cancer Care
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Columbus : Doctors Hospital at Ohio Health
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Columbus : Mount Carmel Health - West Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Columbus : Ohio State University
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Dayton : David L. Rike Cancer Center at Miami Valley Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Dayton : Grandview Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Dayton : CCOP - Dayton
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Dayton : Good Samaritan Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Dayton : Samaritan North Cancer Care Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Delaware : Grady Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elyria : Hematology Oncology Center, Inc
Connect® MM- The Multiple Myeloma Disease Registry
Elyria : Community Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Elyria : Hematology Oncology Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Findlay : Blanchard Valley Medical Associates
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Franklin : Middletown Regional Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville : Wayne Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kettering : Charles F. Kettering Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kettering :
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Lancaster : Fairfield Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Lima : Lima Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Marietta : Strecker Cancer Center at Marietta Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Maumee : Northwest Ohio Oncology Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mount Vernon : Knox Community Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Newark : Licking Memorial Cancer Care Program at Licking Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oregon : St. Charles Mercy Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oregon : Toledo Clinic - Oregon
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Portsmouth : Southern Ohio Medical Center Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Springfield : Community Hospital of Springfield and Clark County
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Sylvania : Flower Hospital Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tiffin : Mercy Hospital of Tiffin
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Toledo : CCOP - Toledo Community Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Toledo : St. Vincent Mercy Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Toledo : Toledo Clinic, Incorporated - Main Clinic
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Toledo : Medical University of Ohio Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Toledo : St. Anne Mercy Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Toledo : Toledo Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Troy : UVMC Cancer Care Center at Upper Valley Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wauseon : Fulton County Health Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Westerville : Mount Carmel St. Ann's Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Wooster : Lawrence M. Stallings MD LTD dba Trilogy Cancer Care
Connect® MM- The Multiple Myeloma Disease Registry
Wright-Patterson Afb : United States Air Force Medical Center - Wright-Patterson
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Xenia : Ruth G. McMillan Cancer Center at Greene Memorial Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Zanesville : Genesis - Good Samaritan Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oklahoma
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Oklahoma City : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Tulsa : Cancer Care Associates
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Oregon
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Clackamas : Clackamas Radiation Oncology Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Coos Bay : Bay Area Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Eugene : Willamette Valley Cancer and Research / USOR
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Eugene : US Oncology - Willamette Valley Cancer Institute - Eugene
Connect® MM- The Multiple Myeloma Disease Registry
Grants Pass : Three Rivers Community Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Gresham : Legacy Mount Hood Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Medford : Providence Cancer Center at PMCC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Medford : Dubs Cancer Center at Rogue Valley Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Milwaukie : Providence Milwaukie Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Newberg : Providence Newberg Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Oregon City : Willamette Falls Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Portland : Oregon Health & Science University
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Portland :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Portland : CCOP - Columbia River Oncology Program
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Portland : Legacy Good Samaritan Hospital & Comprehensive Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Portland : Providence Cancer Center at Providence Portland Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Portland : Providence St. Vincent Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Portland : Oregon Health Science University
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Springfield : Willamette Valley Cancer Institute and Research Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Springfield : US Oncology - Willamette Valley Cancer Institute - Springfield
Connect® MM- The Multiple Myeloma Disease Registry
Springfield :
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Tualatin :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Tualatin : Northwest Cancer Specialists, P.C.
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Tualatin : Legacy Meridian Park Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Pennsylvania
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Allentown : Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bethlehem : Oncology Hematology of Lehigh Valley
Connect® MM- The Multiple Myeloma Disease Registry
Danville : Geisinger Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Drexel Hill : Consultants in Medical Oncology and Hematology, PC
Connect® MM- The Multiple Myeloma Disease Registry
Harrisburg : Andrews and Patel Associates
Connect® MM- The Multiple Myeloma Disease Registry
Kingston : US Oncology - Medical Oncology Associates (Nahar)
Connect® MM- The Multiple Myeloma Disease Registry
Kittanning :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Lancaster : Lancaster Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Philadelphi : University Hospital of Pennsylvania
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Philadelphia : Fox Chase Cancer Center
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Philadelphia : University of Pennsylvania Abramson Cancer Center
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Philadelphia : Fox Chase Cancer Center
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Philadelphia :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Philadelphia : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Philadelphia : Fox Chase Cancer Center
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Philadelphia : Fox Chase Cancer Center
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Philadelphia : Albert Einstein Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Philadelphia : University of Pennsylvania
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Philadelphia : Hospital of the University of Pennsylvania
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Pittsburgh : UPCI Hillman Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Pittsburgh : The Western Pennsylvania Hospital
Connect® MM- The Multiple Myeloma Disease Registry
Pittsburgh : Pittsburgh VA Medical Center
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Reading : Berks Hematology Oncology Associates
Connect® MM- The Multiple Myeloma Disease Registry
Scranton : Scranton Hematology Oncology
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
West Reading : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
West Reading : Reading Hospital and Medical Center
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Rhode Island
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Cranston : Hematology & Oncology Associates of Rhode Island
Connect® MM- The Multiple Myeloma Disease Registry
South Carolina
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Anderson : AnMed Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Charleston : MUSC Hollings Cancer Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Charleston : Medical University of South Carolina Hollings Cancer Center
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
Charleston : Charleston Hematology Oncology Associates, PA
Connect® MM- The Multiple Myeloma Disease Registry
Charleston : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Charleston : Charleston Hematology Oncology Associates, Pa
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Charleston : Hollings Cancer Center at Medical University of South Carolina
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Columbia : South Carolina Oncology Associates
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Easley : US Oncology - Cancer Centers of the Carolinas - Easley
Connect® MM- The Multiple Myeloma Disease Registry
Easley : Cancer Centers of the Carolinas - Easley
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Greenville : Saint Francis Hospital
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Greenville : US Oncology - Cancer Centers of the Carolinas - Butternut
Connect® MM- The Multiple Myeloma Disease Registry
Greenville : US Oncology - Cancer Centers of the Carolinas - Eastside
Connect® MM- The Multiple Myeloma Disease Registry
Greenville : US Oncology - Cancer Centers of the Carolinas - West Faris
Connect® MM- The Multiple Myeloma Disease Registry
Greenville : Cancer Center of the Carolinas
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Greenville : Bon Secours St. Francis Health System
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville : Cancer Centers of the Carolinas - Eastside
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville : Cancer Centers of the Carolinas - Faris Road
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville : Cancer Centers of the Carolinas - Grove Commons
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville : CCOP - Greenville
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville : Greenville Hospital Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greenville :
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Greenwood : Self Regional Cancer Center at Self Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greer : Cancer Centers of the Carolinas - Greer Radiation Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Greer : Cancer Centers of the Carolinas - Greer Medical Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Hilton Head Island : SC Cancer Specialists, PA
Connect® MM- The Multiple Myeloma Disease Registry
Seneca : US Oncology - Cancer Center of the Carolinas - Seneca
Connect® MM- The Multiple Myeloma Disease Registry
Seneca : Cancer Centers of the Carolinas - Seneca
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Spartanburg : US Oncology - Cancer Centers of the Carolinas - Spartanburg
Connect® MM- The Multiple Myeloma Disease Registry
Spartanburg : Cancer Centers of the Carolinas - Spartanburg
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Spartanburg : CCOP - Upstate Carolina
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Spartanburg : Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
South Dakota
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Sioux Falls : Avera Cancer Institute
Connect® MM- The Multiple Myeloma Disease Registry
Sioux Falls : Sanford Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Sioux Falls : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Sioux Falls : Sanford Cancer Center at Sanford USD Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Sioux Falls : Celgene Study Site
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Tennessee
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Chattanooga : Chattanooga Oncology Hematology Associates
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Collierville : Family Cancer Center, PLLC
Connect® MM- The Multiple Myeloma Disease Registry
Cookeville : Cookeville Regional Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Germantown : Jones Clinic
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Kingsport :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Knoxville : Tennessee Cancer Specialists
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Memphis : Family Cancer Center Foundation, Inc.
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Nashville :
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Nashville : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Nashville : Sarah Cannon Research Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Nashville : SCRI
Connect® MM- The Multiple Myeloma Disease Registry
Nashville : Tennessee Oncology, PLLC
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Nashville : The Vanderbilt Clinic
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Nashville : Sarah Cannon Research Institute
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma
Nashville : Tennessee Oncology
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Nashville : Tennessee Oncology, Pllc
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Nashville : Sarah Cannon Research Institute
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Nashville : Sarah Cannon Research Institute
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
Nashville : Sarah Cannon Research Institute Tennessee Oncology Drug Development Unit
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Nashville : Sarah Cannon Research Institute
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Nashville : Tennessee Oncology
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Nashville : Sarah Cannon Research Institute (SCRI) Drug Development Unit
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma
Nashville : Sarah Cannon Research Institute (SCRI) Updated
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Texas
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Abilene : US Oncology - Texas Cancer Center - Abilene (South)
Connect® MM- The Multiple Myeloma Disease Registry
Amarillo : US Oncology - Texas Oncology, PA - Amarillo
Connect® MM- The Multiple Myeloma Disease Registry
Amarillo : Texas Oncology
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Amarillo : Harrington Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Arlington : US Oncology - Texas Oncology - Arlington South
Connect® MM- The Multiple Myeloma Disease Registry
Austin : US Oncology - South Austin Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Austin : US Oncology - Texas Oncology Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Austin : Austin Cancer Centers
Connect® MM- The Multiple Myeloma Disease Registry
Austin : US Oncology - Southwest Regional Cancer Center - North
Connect® MM- The Multiple Myeloma Disease Registry
Austin : US Oncology - Texas Oncology - Midtown
Connect® MM- The Multiple Myeloma Disease Registry
Austin : US Oncology - Texas Oncology North Austin
Connect® MM- The Multiple Myeloma Disease Registry
Bedford :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Bedford : Texas Oncology - Bedford
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Bedford : US Oncology - Texas Oncology, PA - Bedford
Connect® MM- The Multiple Myeloma Disease Registry
Bryan : St. Joseph Regional Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Cedar Park : US Oncology - Texas Oncology Cedar Park
Connect® MM- The Multiple Myeloma Disease Registry
College Station : Scott & White Clinic
Connect® MM- The Multiple Myeloma Disease Registry
Corpus Christi : Coastal Bend Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Corpus Christi : South Texas Institute of Cancer
Connect® MM- The Multiple Myeloma Disease Registry
Corpus Christi : Cancer Specialists Of South Texas, Pa
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Dallas : Baylor Charles A. Sammons Cancer Center at Dallas
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Dallas :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Dallas : Texas Oncology - Dallas Presbyterian
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Dallas : Texas Oncology - Medical City Dallas
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Dallas : US Oncology - Texas Cancer Center at Medical City
Connect® MM- The Multiple Myeloma Disease Registry
Dallas : US Oncology -Texas Oncology, PA - Dallas
Connect® MM- The Multiple Myeloma Disease Registry
Dallas : Mary Crowley Cancer Research Centers Updated
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
El Paso : US Oncology - El Paso Cancer Treatment Ctr
Connect® MM- The Multiple Myeloma Disease Registry
Fort Sam Houston : Brooke Army Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fort Worth : Texas Oncology - Fort Worth 12th Avenue
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Fort Worth : US Oncology - Southwest Forth Worth Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Forth Worth : US Oncology - Texas Oncology, PA - Forth Worth
Connect® MM- The Multiple Myeloma Disease Registry
Ft. Worth :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Galveston : University of Texas Medical Branch
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Garland : US Oncology - Texas Oncology, PA - Garland
Connect® MM- The Multiple Myeloma Disease Registry
Grapevine : US Oncology - Texas Oncology - Grapevine
Connect® MM- The Multiple Myeloma Disease Registry
Houston : MD Anderson Cancer Center
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Houston : MD Anderson Cancer Center
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Houston : MD Anderson Center
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Houston : MD Anderson Cancer Center/University of Texas Dept.ofMDAndersonCancerCtr(SC)
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Houston : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Houston : UT MD Anderson Cancer Center
Acupuncture for Chemo-Induced Peripheral Neuropathy
Houston : MD Anderson Cancer and Research Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Houston : MD Anderson Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Houston : UT MD Anderson Cancer Center
Arry-520 + Carfilzomib for Multiple Myeloma (MM)
Houston : MD Anderson Cancer Center / University of Texas
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Houston : UT MD Anderson Cancer Center
Busulfan Plus Melphalan Versus Melphalan
Houston : UT MD Anderson Cancer Center
Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)
Houston : UT MD Anderson Cancer Center
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
Houston : MD Anderson Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Houston : The Methodist Hospital Research Institute-AOCT
Connect® MM- The Multiple Myeloma Disease Registry
Houston : U T M D Anderson Cancer Center
Dose-escalation Study of Oral CX-4945
Houston : UT MD Anderson Cancer Center
Inflammatory Cytokines in Symptom Production in Multiple Myeloma
Houston : UT MD Anderson Cancer Center
MLN 9708 With Lenalidomide as Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Patients
Houston : University of Texas, MD Anderson Cancer Center
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
Houston : Northwest Cancer Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Houston : The University Of Texas Md Anderson Cancer Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Houston : M. D. Anderson Cancer Center at University of Texas
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Houston : Baylor University Medical Center - Houston
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Houston : Ben Taub General Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Houston : St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Houston : Veterans Affairs Medical Center - Houston
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Houston : MD Anderson Cancer Center
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Houston : Northwest Cancer Center
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Houston : MD Anderson
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function
Houston : Houston VA Medical Center
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Irving : Southlake Oncology dba Las Colinas Hematology Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Kerrville :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Kerrville : US Oncology - San Antonio Tumor & Blood Clinic - Kerrville
Connect® MM- The Multiple Myeloma Disease Registry
Kyle : US Oncology - Texas Oncology - Kyle
Connect® MM- The Multiple Myeloma Disease Registry
Longview : US Oncology - Longview Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Lubbock : Joe Arrington Cancer Research and Treatment Center
Connect® MM- The Multiple Myeloma Disease Registry
Midland : US Oncology - Allison Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Odessa : US Oncology - Texas Oncology - Odessa
Connect® MM- The Multiple Myeloma Disease Registry
Plano : US Oncology - North Texas Regional Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Plano : US Oncology - Texas Oncology Plano West Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Round Rock : Texas Oncology - Central Austin Cancer Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Round Rock : US Oncology - Texas Oncology Seton Williamson
Connect® MM- The Multiple Myeloma Disease Registry
Roundrock : US Oncology - Texas Oncology - Round Rock Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
San Antonio :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
San Antonio : University of Texas Health Science Center
BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma
San Antonio : US Oncology - Cancer Care Centers of South Texas
Connect® MM- The Multiple Myeloma Disease Registry
San Antonio : US Oncology - HOAST - Medical Dr.
Connect® MM- The Multiple Myeloma Disease Registry
San Antonio : US Oncology - San Antonio Tumor & Blood Clinic - M. Oak
Connect® MM- The Multiple Myeloma Disease Registry
San Antonio : South Texas Accelerated Research Therapeutics (START)
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
San Antonio : University Hospital - San Antonio
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
San Antonio : Cancer Therapy and Research Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
San Antonio : University of Texas Health Science Center at San Antonio
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
San Antonio : Veterans Affairs Medical Center - San Antonio (Murphy)
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
San Antonio : South Texas Accelerated Research Therapeutics, LLC (START)
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
San Antonio : Cancer Therapy and Research Center at the UT Health Sciences Center at San Antonio
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
San Marcos : US Oncology - Texas Oncology - San Marcos
Connect® MM- The Multiple Myeloma Disease Registry
Temple : Scott & White Healthcare Department of Research
Connect® MM- The Multiple Myeloma Disease Registry
Temple : Scott & White Healthcare
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Temple : CCOP - Scott and White Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tyler :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Tyler : ETMC dba Blood and Cancer Center - East Texas
Connect® MM- The Multiple Myeloma Disease Registry
Tyler : ETMC dba Tyler Hematology Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Waco : Texas Oncology - Waco
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Waco : US Oncology - Texas Oncology Cancer Care and Research Center
Connect® MM- The Multiple Myeloma Disease Registry
Wichita Falls : US Oncology - Texoma Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Utah
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
American Fork : Central Utah Clinic
Connect® MM- The Multiple Myeloma Disease Registry
American Fork : American Fork Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Cedar City : Sandra L. Maxwell Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Logan : Logan Regional Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Murray : Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Ogden :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Ogden : Northern Utah Associates
Connect® MM- The Multiple Myeloma Disease Registry
Ogden : Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Provo : Utah Valley Regional Medical Center - Provo
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Saint George : Dixie Regional Medical Center - East Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Salt Lake City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Salt Lake City : Huntsman Cancer Institute
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Salt Lake City : University of Utah - Huntsman Cancer Institute
Connect® MM- The Multiple Myeloma Disease Registry
Salt Lake City : Huntsman Cancer Institute
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Salt Lake City : Huntsman Cancer Institute
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Salt Lake City : LDS Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Salt Lake City : Huntsman Cancer Institute at University of Utah
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Salt Lake City : Utah Cancer Specialists at UCS Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Vermont
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
Virginia
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Arlington : US Oncology - Arlington Fairfax Hematology Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Charlottesville : University of Virginia Health System
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Christianburg : Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Christiansburg :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Christiansburg : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Fairfax : Virginia Cancer Specialists, PC
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Fairfax : US Oncology - Fairfax-Northern VA Hem-Onc PC
Connect® MM- The Multiple Myeloma Disease Registry
Fairfax : Virginia Cancer Specialists
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Fredericksburg : Fredericksburg Oncology, Incorporated
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Fredricksburg : Hematology-Oncology Associates Of Fredricksburg, Inc
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Gainesville : US Oncology - Fairfax Northern Virginia Hematology-Oncology, PC-Gainesville
Connect® MM- The Multiple Myeloma Disease Registry
Leesburg : US Oncology - Fairfax-Northern Virgina Hem-Onc, PC-Leesburg
Connect® MM- The Multiple Myeloma Disease Registry
Newport News : Peninsula Cancer Institute
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Norfolk :
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Richmond : Virginia Commonwealth University
Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma
Richmond : Virginia Commonwealth University
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Richmond : Massey Cancer Center/Virginia Commonwealth University
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Roanoke :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Salem :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Winchester : US Oncology - Shenandoah Oncology - Winchester
Connect® MM- The Multiple Myeloma Disease Registry
Woodbridge : US Oncology - Fairfax-Northern Virginia Hem-Onc, PC-Woodbridge
Connect® MM- The Multiple Myeloma Disease Registry
Washington
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Anacortes : Island Hospital Cancer Care Center at Island Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bellingham : Peace Health Medical Group
Connect® MM- The Multiple Myeloma Disease Registry
Bellingham : St. Joseph Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Bremerton : Olympic Hematology and Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Burien : Highline Medical Center Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Centralia : Providence Centralia Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Edmonds : Puget Sound Cancer Centers
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Edmonds : US Oncology - Puget Sound Cancer Center-Edmonds
Connect® MM- The Multiple Myeloma Disease Registry
Everett : Providence Everett Medical Center
Connect® MM- The Multiple Myeloma Disease Registry
Everett : Providence Regional Cancer Partnership
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Federal Way : St. Francis Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Issaquah : Swedish Medical Center - Issaquah Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kennewick : Columbia Basin Hematology and Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Kennewick : Columbia Basin Hematology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Kirkland : Cascade Cancer Center at Evergreen Hospital Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Mount Vernon : Skagit Valley Hospital Cancer Care Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Olympia : Providence St. Peter Hospital Regional Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Poulsbo : Harrison Poulsbo Hematology and Onocology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Puyallup : Good Samaritan Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Fred Hutchinson Cancer Research
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Seattle : Fred Hutchinson Cancer Research Center
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Seattle : Fred Hutchinson Cancer Research Center
A Safety Study of Carfilzomib With Cyclophosphamide and Dexamethasone Prior to Autologous Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma
Seattle : Fred Hutchinson Cancer Research Center
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Seattle : University Of Washington School Of Medicine
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Seattle :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Seattle : US Oncology - Puget Sound Cancer Center-Seattle
Connect® MM- The Multiple Myeloma Disease Registry
Seattle : Fred Hutchinson Cancer Research Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Seattle : CCOP - Virginia Mason Research Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : University Cancer Center at University of Washington Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Fred Hutchinson Cancer Research Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Group Health Central Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Harborview Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Minor and James Medical, PLLC
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Pacific Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Polyclinic First Hill
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Virginia Mason Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Seattle : Fred Hutchinson Cancer Research Institute
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
Sedro-Woolley : North Puget Oncology at United General Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Spokane :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Spokane : Medical Oncology Associates PS
Connect® MM- The Multiple Myeloma Disease Registry
Spokane : US Oncology - Cancer Care Northwest - Sherman
Connect® MM- The Multiple Myeloma Disease Registry
Spokane : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Spokane : Cancer Care Northwest - Spokane South
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Spokane : Evergreen Hematology and Oncology, PS
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Spokane Valley : Cancer Care Northwest
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Tacoma : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Tacoma : CCOP - Northwest
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tacoma : MultiCare Regional Cancer Center at Tacoma General Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tacoma : St. Clare Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tacoma : Allenmore Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Tacoma : Franciscan Cancer Center at St. Joseph Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Vancouver :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Vancouver : Legacy Salmon Creek Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Vancouver : Southwest Washington Medical Center Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Walla Walla : Providence St. Mary Regional Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Wenatchee : Wenatchee Valley Medical Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Yakima : Yakima Regional Cancer Care
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Yakima : Yakima Valley Memorial Hospital / North Star Lodge
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Yakima : US Oncology - Yakima Valley Memorial Hospital/North Star Lodge
Connect® MM- The Multiple Myeloma Disease Registry
Yakima :
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
West Virginia
Morgantown : West Virginia University - Clinical Trials Research Unit
BMTCTN0702 - A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma.
Morgantown : West Virginia University - Clinical Trials Research Unit
C16006- An Open-Label, Dose Escalation
Morgantown : West Virginia University - Clinical Trials Research Unit
C16010 A Phase 3, Double-blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone
Morgantown : West Virginia University - Clinical Trials Research Unit
CC-4047-MM-009 A Multicenter, Single-Arm, Open-Label Treatment Use Program For Pomalidomide (POM)
Morgantown : West Virginia University - Clinical Trials Research Unit
PRE1003 A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone
Morgantown : West Virginia University - Clinical Trials Research Unit
SNS01-T-001 - Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Huntington : Edwards Comprehensive Cancer Center
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Morgantown : West Virginia University
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Morgantown : West Virginia University - Clinical Trials Research Unit
Connect® MM- The Multiple Myeloma Disease Registry
Morgantown : WVU Mary Babb Randolph Cancer Center
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Morgantown : West Virginia University Mary Babb Randolf Cancer Center
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
Morgantown : Mary Babb Randolph Cancer Center/WVU
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Wisconsin
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Appleton : Fox Valley Hematology & Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Green Bay : St. Vincent Hospital/Green Bay Oncology
Connect® MM- The Multiple Myeloma Disease Registry
Green Bay : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Green Bay : Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Green Bay : St. Vincent Hospital Regional Cancer Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Green Bay : Green Bay Oncology, Limited at St. Mary's Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Green Bay : St. Mary's Hospital Medical Center - Green Bay
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
La Crosse : Gundersen Lutheran
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
La Crosse : Gundersen Clinic, Ltd
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
La Crosse : Gundersen Lutheran Center for Cancer and Blood
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Madison : University of Wisconsin
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Madison : Dean Clinic-Hematology And Oncology
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Manitowoc : Holy Family Memorial Medical Center Cancer Care Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Milwaukee : Medical College of Wisconsin
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Milwaukee : Froedtert & Medical College of Wisconsin-CLCC
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Milwaukee :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Milwaukee : CMS Water Tower Medical Commons Medical Oncology #100
Connect® MM- The Multiple Myeloma Disease Registry
Milwaukee : MCW and Froedtert Clinical Cancer Center, Division of Neoplastic Diseases & Related Disorders
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Milwaukee : Medical College of Wisconsin/Froedtert Hospital
Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Milwaukee : Medical College of Wisconsin - Clinical Cancer Center
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Minocqua : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Oconto Falls : Green Bay Oncology, Limited - Oconto Falls
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Sheboygan : St. Nicholas Hospital
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Sturgeon Bay : Green Bay Oncology, Limited - Sturgeon Bay
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Waukesha : Waukesha Memorial Hospital
Connect® MM- The Multiple Myeloma Disease Registry
Waukesha : Waukesha Memorial Hospital (ProHealth Care)
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Wyoming
Various Cities : Millennium Pharmaceuticals
An Open Label Phase I/II Study Evaluating Three and Four Drug Combinations of Velcade, Dexamethasone, Cyclophosphamide, and Revlimid in Patients with Newly Diagnosed Multiple Myeloma
View More »
Casper : Rocky Mountain Oncology
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Australia
Adelaide : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Adelaide :
Velcade (Bortezomib) Consolidation After Transplant
Box Hill : Box Hill Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Brisbane : Princess Alexandra Hospital - Haematology
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Camperdown :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
View More »
Camperdown :
Velcade (Bortezomib) Consolidation After Transplant
Canberra : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Darlinghurst : St. Vincent's Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Douglas : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
East Melbourne :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
East Melbourne : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Epping : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Fitzroy : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Frankston : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Geelong :
Velcade (Bortezomib) Consolidation After Transplant
Greenslopes :
Velcade (Bortezomib) Consolidation After Transplant
Harston : Royal Brisbane and Women's Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Heidelberg :
Velcade (Bortezomib) Consolidation After Transplant
Heidelberg Melbourne : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Herston : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Herston :
Velcade (Bortezomib) Consolidation After Transplant
Hobart : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Liverpool : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Malvern :
Velcade (Bortezomib) Consolidation After Transplant
Melbourne : Peter MacCallum Cancer Centre
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
Melbourne : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Melbourne : The Alfred Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Nedlands : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Nedlands :
Velcade (Bortezomib) Consolidation After Transplant
Newcastle :
Velcade (Bortezomib) Consolidation After Transplant
Nsw 2298 : Calvary Mater Newcastle
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Parkville : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Perth : Royal Perth Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Perth : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Prahran : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Prahran :
Velcade (Bortezomib) Consolidation After Transplant
Randwick :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
South Brisbane : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
South Brisbane : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Sydney :
Velcade (Bortezomib) Consolidation After Transplant
Tweed Heads : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Waratah : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Westmead : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Westmead N/A :
Velcade (Bortezomib) Consolidation After Transplant
Wodonga : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Woodville South : The Queen Elizabeth Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Woodville South :
Velcade (Bortezomib) Consolidation After Transplant
Woolloongabba :
Velcade (Bortezomib) Consolidation After Transplant
Austria
Graz : Medizinische Universität Graz
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Graz :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Graz : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Graz : University Hospital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Innsbruck : Universitätsklinikum Innsbruck
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
View More »
Innsbruck :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Innsbruck : Medical University Innsbruck, Division of Hematology and Oncology
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Innsbruck : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Linz : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Rankweil : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Salzburg : Salzburger Landeskliniken
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Salzburg : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Salzburg : University Hospital Salzburg, Department of Medicine III, Center of Oncology and Hematology
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Vienna : AKH Vienna
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Vienna : Wilhelminenspital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Vienna : Wilhelminenspital, Department of Medicine I, Center of Oncology and Hematology
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Wels : Klinikum Wels-Grieskirchen GmbH
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Wels : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Wien : Allgemeines Krankenhaus Wien, Währinger Gürtel 18-20
A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
Wien : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Belgium
Andtwerpen : ZNA AZ Stuivenberg
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Antwerpen :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Antwerpen :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Antwerpen : Lange Beeldekensstraat
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Brussel : Universitair Ziekenhuis Brussel
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
View More »
Brussels : UCL Saint Luc
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Brussels : UZ Brussels
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Brussels :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Brussels :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Brussels : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Brussles : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Charleroi : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Edegem-Antwerp : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Gent :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Gent :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Haine St Paul : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Leuven : UZ Gasthuisberg
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Leuven : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Liege : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Mons : CHU Ambroise Pare
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Roeselare : H.-Hartziekenhuis Roeselare-Menen
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Roeselare : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Yvoir : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Brazil
Bulgaria
Pleven : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Plovdiv : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Plovdiv : University Hospital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Sofia : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Sofia : Tokuda Hospital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
View More »
Varna : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Canada
Barrie : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Burnaby : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Calgary : Tom Baker Cancer Centre
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Calgary : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Calgary : Tom Baker Cancer Centre
Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma
View More »
Edmonton : Cross Cancer Centre
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Edmonton : Cross Cancer Institute
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Edmonton : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Halifax : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Halifax : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Laval : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
London : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Moncton : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Montréal : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Montral : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Montreal : Royal Victoria Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Montreal :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Montreal : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Newmarket : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Ontario : London Health Sciences Centre
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Ontario : The Ottawa Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Quebec : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Quebec : CHA/Québec-Hôpital Enfant-Jésus
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Quebec City :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Saint John : Saint John Regional Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Saint John : Saint John Regional Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Saint John : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Saskatoon : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Sault Ste. Marie : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
St. Johns : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Toronto : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Toronto : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Toronto : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Toronto : University Health Network, Princess Margaret Hospital
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Vancouver : Vancouver General Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Vancouver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Vancouver : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Vancouver : Vancouver General Hospital
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Windsor : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Windsor : Windsor Regional Cancer Program
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Winnipeg :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Winnipeg : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
China
Beijing : Beijing Clinical Service Center
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
Tianjin : Hematologic Hospital of Chinese Academy of Medical Sciences
Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma
Croatia
Zagreb :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Czech Republic
Brno : Fakultni nemocnice Brno
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Brno : Fakultni nemocnice Ostrava
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Brno :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Brno : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Brno : Fakultni nemocnice Brno
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
View More »
Brno : Fakultni nemocnice Brno
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Hradec Kralove : Fakultni nemocnice Hradec Kralove
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Hradec Kralove : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Olomouc : Fakultni Nemocnice Olomouc
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Olomouc : Fakultni nemocnice Olomouc
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Ostrava : Fakultni nemocnice Ostrava
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Ostrava-Poruba : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Plzen : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Prague :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Prague : Všeobecná fakultní nemocnice v Praze
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Praha 10 : Fakultni Nemocnice Kralovske Vinohrady
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Praha 10 : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Praha 10 : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Praha 2 : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Sokolska : Fakultni nemocnice Hradec Kralove
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Srobarova : Fakultni nemocnice Kralovske Vinohrady
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Znojmo : Nemocnice Znojmo
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Denmark
Copenhagen : Rigshospitalet Clinic of Hematology L4042
Daratumumab(HuMax®-CD38)Safety Study in Multiple Myeloma
Odense :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Vejle : Vejle Sygehus
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Vejle : Vejle Hospital
Daratumumab(HuMax®-CD38)Safety Study in Multiple Myeloma
Estonia
Tallinn N/A :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Tartu :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Finland
Helsinki : Helsinki University Hospital Hemat Dept
Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Kuopio : Kuopio University Hospital
First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02
France
Amiens Cedex 1 : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Avignon Cedex 9 :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Bayonne : Centre Hospitalier de la côte basque - Hematologie
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Blois Cedex :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Bordeaux : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
View More »
Bordeaux Cedex :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Brest Cedex 2 :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Caen : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Caen : Chru Caen
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Cedex : Centre Hospitalier de lo Cote Baque
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Cedex : Centre Hospitalier Lyon-Sud
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Clermont Ferrand : CHU Estaing
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Clermont Ferrand Cedex 2 :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Corbeil Essonne : Centre Hospitalier Sud Francilien
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Créteil : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Dijon :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Dijon : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Dijon : CHU DIJON, Hôpital d'Enfants
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Grenoble : CHRU, Hôpital A.Michallon
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Grenoble Cedex 9 : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Le Kremlin Bicêtre : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Le Mans : CH Le Mans
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Le Mans : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Le Mans : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Le Mans Cedex 9 :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Le Mans Cedex 9 : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Lille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Lille : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Lille : Chru Lille
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Lille : CHRU de Lille - Service des maladies du sang
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Lille Cedex :
A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma
Lille cedex : CHRU de Lille, Hopital Huriez
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Lille Cedex : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Limoges : Hôpital Universitaire Dupuytren
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Lyon : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Lyon : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Marseille : Hôpital Ambroise Paré
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Marseille : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Marseille : Institut Paoli Calmette,
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Marseille Cedex : Institut Paoli Calmettes
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Marseille cedex 5 : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Marseille Cedex 9 : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Montpellier :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Montpellier cedex 5 : Hôpital Saint Eloi
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Nantes :
A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma
Nantes : Hôtel-Dieu
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Nantes : Hôpital de l'Hôtel Dieu
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Nantes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Nantes : CHRU, Hôtel Dieu
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Nantes : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Nantes Cedex 1 :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Nantes Cedex 1 : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Nantes N/A :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Nice Cedex 3 : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Nimes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Nîmes :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Nîmes Cedex 9 :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Paris : Hôpital Saint Antoine
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Paris : Hôpital Saint Louis
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Paris : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Paris : Hôpital Européen Georges Pompidou - Service Oncologie Médicale
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Paris : Hopital Saint Antoine
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Paris : Hopital Saint Louis - Service d'Immuno-Hematologie
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Paris : CHU - Hôpital St Antoine,
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Paris : Hôpital Saint-Louis
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Paris : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Paris : CHU Saint Antoine - Service des maladies du sang
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Paris : Hôpital Saint Louis - Immuno-hematologie
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Paris Cedex 12 : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Paris Cedex 14 : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Perpignan : Centre Hospitalier Saint Jean
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Perpignan Cedex :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Pessac : Hôpitaux du Haut Leveque
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Pessac Cedex : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Pierre Benite : Centre Hospitalier Lyon Sud -2
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Pierre Benite : Centre Hospitalier Lyon Sud -1
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Pierre-Bénite cedex : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Pierre-Benite : Centre Hospitalier Lyon sud - Hematologie
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Pontoise :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Rennes :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Rennes : CHRU RENNES 2, Hôpital Pontchaillou
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Rennes cedex 9 : Hôpital Pontchaillou 2 Rue Henri le Guilloux
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Rouen : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Rouen Cedex : Centre Henri Becquerel
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Saint Herblain : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
St Brieuc Cedex 1 :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Strasbourg : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Toulouse : Hopital Purpan
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Toulouse : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Toulouse : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Toulouse Cedex : Institut Claudius Régaud Updated
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Tours :
A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma
Tours :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Tours : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Tours : Hôpital Bretonneau - Hématologie & Thérapie cellulaire
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Tours cedex : Hôpital Bretonneau
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Troyes Cedex :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Vandoeuvre : CHRU, Hôpitaux de Brabois
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Vandoeuvre Les Nancy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Vandoeuvre Les Nancy : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Vandoeuvre-les-Nancy : CHU Nancy - Hematologie
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Villefranche Sur Saone Cedex : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Villejuif :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Villejuif : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Villejuif Cedex : Institut Gustave Roussy, Dept. of Medicine Updated
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Germany
Aschaffenburg : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Berlin :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Berlin : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Chemnitz : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Dresden : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
View More »
Essen : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Flensburg : Malteser Krankenhaus St. Franziskus-Hospital, medizinische Klinik I
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Freiburg : Universitätsklinikum Freiburg, Abteilung für Innere Medizin I
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Freiburg : University Hospital Freiburg, Medizinische Universitätsklinik, Innere Medizin I, Haematologie und Onkologie
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Freiburg : University Medical Center Freiburg
Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)
Hamburg : Universitaetsklinik Hamburg-Eppendorf, Med. Klinik II Onkologie, Haematologie
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Hamm : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Heidelberg : Universitäsklinikum Heidelberg, Klin.-Pharmakologisches Studienzentrum, Im Neuenheimer Feld 410
A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
Heidelberg :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Heidelberg : University Hospital of Heidelberg, Department V
Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy
Heidelberg : Department of Internal Medicine V
Exploratory Study on POL6326 in Stem Cell Mobilization
Heidelberg : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Jena : Klinikum der Friedrich-Schiller-Universität Jena, Klinikum für Innrere Medizin II
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Jena : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Kiel : Universitätsklinikum Schleswig-Holstein Campus Kiel, II. Med. Poliklinik
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Koeln : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Koln : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Leipzig : Universitätsklinikum Leipzig - Medizinische Klinik und Poliklinik II
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Leipzig : University of Leipzig
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
Lübeck : Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Medizinische Klinik I
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Mainz : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Mannheim : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Munchen : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
München : III. Med. Klinik und Poliklinik, Klinikum rechts der Isar der TU München
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Munich : Klinikum rechts der Isar/ Studien / III. Med. Klinik/ Ismaninger Str. 22
A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
Munster : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Münster : University Hospital Münster, Medizinische Klinik und Poliklinik A
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Offenbach : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Oldenburg : Klinikum Oldenburg GmbH, Klinik für Innere Medizin II
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Regensburg : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Stuttgart : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Tübingen : Universitätsklinikum Tübingen - Medizinische Klinik und Poliklinik - Abteilung II
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Tuebingen : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ulm : Universitätsklinikum Ulm,Klinik für Innere Medizin III
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Ulm : University Hospital Ulm, Zentrum für Innere Medizin,
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Ulm : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ulm : Universitätsklinikum Ulm - Klinik fur Innere Medizin III
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Villingen-Schwenningen : Schwarzwald-Baar Klinkum Villingen-Schwennigen GmbH
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Wuerzburg : Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II
Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma
Würzburg : Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Studienambulanz für Hämatologie/Onkologie und Infektiologie, Oberdürrbacher Straße 6
A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
Würzburg : University Hospital Würzburg, Hämatologie/Onkologie und Early Clinical Trial Unit (ECTU) Zentrum für Innere Medizin (ZIM)
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Greece
Ampelokipoi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Athens : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Athens : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Athens : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Heraklion : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
View More »
Ioannina : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Larissa : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Patra : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Patras : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Thessaloniki : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Hong Kong
Hong Kong : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
New Territories : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Shatin, N.T. : Department of Clinical Oncology, Prince of Wales Hospital
Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Hungary
Budapest : Egyesitett Szent Istvan es Szent Laszlo Korhaz
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Budapest :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Budapest : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Budapest : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Debrecen : Debreceni Egyetem Orvos- és Egészségtudományi Cent
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
View More »
Debrecen : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Gyula : Pándy Kálmán Megyei Kórház
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Gyula : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Kaposvar : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Kaposvar : Somogy Megyei Kaposi Mor Oktato Korhaz
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Pécs N/A :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Szeged :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Szeged : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Szombathely :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Ireland
Co Galway : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Co-Limerick : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Dublin : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Dublin : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Dublin 24 :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
View More »
Dublin 7 : Keryx / AOI Pharmaceuticals Investigative Site
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Dublin 8 :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Dublin 9 :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Galway :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Galway : GSK Investigational Site
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Limerick :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Sligo :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Tullamore :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Tullamore : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Waterford :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Israel
Afula :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Afula : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ashkelon :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Ashkelon :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Ashkelon : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
View More »
Beer Sheva :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Haifa : Rambam Medical Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Haifa :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Haifa :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Haifa : Rambam Health Care Campus
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Jerusalem : Hadassah University Hospital Ein Kerem
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Jerusalem :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Jerusalem : Hadassah University Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Jerusalem : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Kfar Saba : Meir Medical Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Kfar Saba :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Naharia :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Nahariya : Western Galilee Hospital - Nahariya
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Nahariya :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Nahariya : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Petach Tikva :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Petach Tikva :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Petah Tikva :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Petah Tikva : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Petah-Tikva :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Ramat Gan :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Ramat Gan : Sheba MC
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
Rehovot : Kaplan Medical Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Rehovot :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Rehovot : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Tel Aviv : Tel Aviv Sourasky Medical Center
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Tel Aviv :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Tel Aviv : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Tel-Hashomer :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Zerifin : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Italy
Ancona : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Ancona : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ancona : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Bari : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Bari : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
View More »
Bergamo : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Bergamo : USC Ematologia, Azienda Ospedaliera Papa Giovanni XXIII
SST0001 in Advanced Multiple Myeloma
Bologna : Azienda Ospedaliero-Universitaria di Bologna - Pol
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Bologna : Istituto de Ematologia ed Oncologia Medica
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Bologna : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Bologna : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Bologna : Università degli Studi di Bologna - Policlinico S. Orsola - Hematology
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Bolzano : Division of Hematology and CBMT
Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Brescia : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Brescia : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Catania : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Catania : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Fierenze : Azienda Ospedaliera Universitaria Careggi
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Firenze : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Firenze : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Firenze : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Firenze : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Genova : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Genova : University Hospital San Martino, Department of Hematology and Oncology
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Genova : IRCCS Azienda Ospedaliera Universitaria San Martino
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Genova : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Genova : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Meldola : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Milano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Milano : Niguarda Ca'Granda Hospital, Department of Hematology
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Milano : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Milano : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Modena : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Monza : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Naples : AORN
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Napoli : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Napoli : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Napoli : Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Novara : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Novara : Azienda Ospedaliera Universitaria Maggiore
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Palermo : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Palermo : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Parma : Azienda Ospedaliero Universitaria di Parma
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Pescara : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Pescara : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Piacenza : Ospedale Guglielmo da Saliceto - hematooncology
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Pisa : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Ravenna : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Ravenna : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Rimini : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Rimini : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Roma : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Roma : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Roma : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Roma : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Rome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Rome : Sapienza University of Rome, Department of Hematology
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
Rome : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Rozzano MI : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Terni : Azienda Ospedaliera S. Maria di Terni
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Torino : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Torino : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Torino : Azienda Ospedaliero Universitaria "San Giovanni Battista di Torino"
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Torino : Azienda Ospedaliera Universitaria San Giovanni
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Torino : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Torino : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Torino : A.O.U. San Giovanni Battista - Hematology
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Udine : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Vimercate MB : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Japan
Aichi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma
Akita-shi : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Fukuoka : Celgene Trial Sites
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma
Isehara : Celgene Trial Site
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
View More »
Kamogawa : Clinical Trial Site
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Kamogawa-shi : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma
Kawagoe : Celgene Trial Sites
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Kawagoe-shi : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Kumamoto-shi : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Kyoto :
Efficacy Study of SyB L-0501 for Patients With Multiple Myeloma
Kyoto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma
Kyoto-shi : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Maebashi-shi : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Nagoya : Celgene Trial Sites
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Nagoya :
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
Nagoya-shi : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Niigata : Celgene Trial Sites
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Ogaki-shi : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Okayama-shi : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Shibukawa-shi : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Shibuya-ku : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Tokushima-shi : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Tokyo : Celgene Trial Site
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Tokyo :
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma
Toyama-shi : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Korea, Republic of
Anyang : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Busan :
Velcade (Bortezomib) Consolidation After Transplant
Daegu : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Daejeon :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Daejeon : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
View More »
Goyang-Si : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Gwangju : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Hwasun Gun :
Velcade (Bortezomib) Consolidation After Transplant
Hwsun-eup, Hwasun-gun : Je-Jung Lee
TCD Followed by autoSCT for Newly Diagnosed MM Patients
Incheon : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Inchon : Gachon University Gil Hospital
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Seoul :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Seoul :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Seoul : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Seoul : Seoul National University Hospital
Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM
Seoul : Novartis Investigative Site
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Latvia
Riga :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Lithuania
Klaipeda :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Vilnius :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Macedonia, The Former Yugoslav Republic of
Skopje :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Malaysia
Georgetown : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Ipoh : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Kuching : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Mexico
Netherlands
Amsterdam : VU Medical Center
Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Nieuwegein : Antonius Ziekenhuis Nieuwegein
Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Utrecht : Uni.Med Center Utrecht
Daratumumab(HuMax®-CD38)Safety Study in Multiple Myeloma
Utrecht : UMC Utrecht
Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
New Zealand
Auckland : Middlemore Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Auckland : Auckland City Hospital, Auckland District Health Board
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Auckland : Middlemore Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Auckland City : North Shore Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Christchurch : Canterbury Health Laboratories
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
View More »
Christchurch : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Christchurch : Canterbury Health Laboratories
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Christchurch : Christchurch Hospital
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Grafton Auckland : Auckland City Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Grafton, Auckland : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Hamilton : Waikato Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Newtown, Wellington : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Palmerston North : Palmerston North Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Wellington : Wellington Regional Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Poland
Bialystok :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Bialystok : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Brzozow :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Bytom :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Chorzow :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
View More »
Chorzow : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Gdansk :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Katowice :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Krakow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Legnica :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Lublin :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Lublin : SPSK1 Klinika Hematologii
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Lublin : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Opole :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Poznan :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Poznan : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Rzeszow :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Slupsk :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Slupsk : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Warsaw : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Warszawa :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Warszawa : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Warszawa : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Warszawa Poland :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Wroclaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Wroclaw :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Wroclaw : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Wroclaw : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Zamosc : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Zamosc :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Portugal
Coimbra : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Lisboa : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Matosinhos : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Porto : Instituto Portugues de Oncologia do Porto Francisc
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Porto : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Puerto Rico
Ponce : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
San Juan : Auxilio Cancer Center
Connect® MM- The Multiple Myeloma Disease Registry
Romania
Brasov : Emergency County Clinical Hospital Brasov
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Brasov : Spitalul Judetean
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Brasov : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Bucaresti : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Bucharest : "Coltea" Clinical Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
View More »
Bucharest : Emergency University Hospital
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Bucuresti : Centrul de Diagnostic si Tratament Euromedic Fundeni
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Bucuresti : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Cluj-Napoca : Institutul Oncologic
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Craiova : Spitalul Municipal
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Lasi : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Timisoara : Oncomed
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Russian Federation
Ekaterinburg : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Krasnodar :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Krasnogorsk :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Moscow :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Moscow : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
View More »
Nizhny Novgorod : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Novosibirsk : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Petrozavodsk : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Petrozavodsk : State Healthcare Institution "Republican Hospital named after V.A. Baranov"
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Podolsk :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Saint Petersburg :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Saint Petersburg : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Saint-Petersburg :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Saint-Petersburg : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Samara :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Samara : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Samara : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Saransk :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
St Petersburg :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
St. Petersburg : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
St. Petersburg : Federal State Institution "Russian Scientific and Research Institute of Hematology and Transfusiology" of Federal Medical Biological Agency
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Ulyanovsk :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Volgograd : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Vologda :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Saudi Arabia
Riyadh : King Faisal Specialist Hospital and Research Center
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Singapore
Singapore : Novartis Investigative Site
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Singapore : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Singapore : National University Hospital (Cancer Institute)
Phase 1 Pharmacokinetic Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma
Singapore : National University Cancer Institute
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Slovakia
Kosice :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Slovenia
Ljubljana :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Spain
Alcalá de Henares : Hospital Principe de Asturias Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Alcorcón : Fundación Hospital Alcorcón Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Badalona :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Badalona :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Badalona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
View More »
Badalona :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Badalona : Hospital Germans Trias i Pujol Updated
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Badalona : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Badalona : Hospital de Badalona Germans Trias i Pujol Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Badalona : Hospital Germans Trias i Pujol - Hematology
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Badalona : Hospital Universitari Germans Trias I Pujol Updated
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
Badalona-Barcelona : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Barcelona : Hospital Clinic de Barcelona
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Barcelona : Hospital de la Santa Creu i Sant Pau
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Barcelona :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Barcelona :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Barcelona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Barcelona : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Barcelona :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Barcelona : Institut català d'Oncología Updated
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Barcelona : Hospital Clínic Updated
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Barcelona : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Barcelona : Hospital Clinic i Provincial de Barcelona
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Barcelona : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Barcelona : Local Institution
Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Barcelona : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Barcelona : Hospital Clínic i Provincial de Barcelona
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Barcelona : Hospital Universitari Germans I Pujol
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Barcelona : Hospital de la Santa Creu i Sant Pau Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Barcelona : Hospital del Mar Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Barcelona : H. Vall d'Hebron, Barcelona Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Barcelona : ICO - Duran i Reynals, Hospitalet de Llobregat Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Barcelona : Hospital Clinic i Provincial de Barcelona Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Barcelona : Hospital de la Santa Creu i Sant Pau Updated
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
Barcleona :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Barcleona :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Bilbao : Hospital de Cruces Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Cáceres : Complejo Hospitalario de Cáceres Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Cádiz : Hospital Puerta del Mar Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Castellón : Hospital General de Castellón Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Ciudad Real : Hospital General Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Cuenca : Hospital Virgen de la Luz Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Donostia : Hospital Donostia Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Gandía : Hospital Francesc Borja Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Girona : ICO - Josep Trueta Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Guadalajara : Hospital General de Guadalajara Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Jerez de la Frontera : H. de Jerez Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
La Laguna :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Lalaguna-S. Cruz Tener : Local Institution
Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Leon : Complejo Hospitalario León Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
L'Hospitalet De Llobregat :
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
Madrid : Hospital General Universitario Gregorio Marañon
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Madrid :
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Madrid : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)
Madrid : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Madrid :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Madrid : MD Anderson Internacional Updated
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Madrid : Hospital Universitario Ramón y Cajal Updated
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Madrid : Hospital Universitario de la Princesa Updated
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Madrid : Hospital 12 de Octubre Updated
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Madrid : Hospital Clínico San Carlos Updated
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Madrid : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Madrid : Centro Integral Oncologico Clara Campal
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Madrid : Local Institution
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Madrid : Local Institution
Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Madrid : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Madrid : Hospital Universitario de La Princesa
Study of Oral MLN9708 in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma
Madrid : Clínica Puerta de Hierro Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital Clinico San Carlos Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital del Tajo Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital de Madrid, S.A.- Norte Hospital General Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital de Fuenlabrada Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital Infanta Sofia Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital la Paz Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : MD Anderson Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital Severo Ochoa Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital Universitario Gregorio Marañón Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital Infanta Leonor Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital Ramón y Cajal Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital de la Princesa Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital 12 de Octubre. Madrid Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Madrid : Hospital de La Princesa - Hematology
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Madrid : Hospital Universitario Ramón y Cajal Updated
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
Madrid : Hospital Clínico San Carlos Updated
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
Málaga : Hospital Universitario Virgen de la Victoria Updated
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Málaga : Complejo Hospital Costa del Sol Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Málaga : Hospital Nuestra Señora de Valme Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Manresa : Althaia Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Marbella : Hospital Costa del Sol
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Murcia : Hospital General Morales Messeguer Updated
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Murcia : Local Institution
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Murcia : Hospital General Univeristario Morales Messeguer Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Murcia : Hospital Virgen de la Arrixaca Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Navarra : Hospital de la Diputación de Navarra Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Ourense : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Oviedo : Updated
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers
Oviedo : Hospital Universitario Central de Asturias Updated
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Palma de Gran Canaria : Hospital de Gran Canaria Doctor Negrín Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Palma de Mallorca : Research Site Updated
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Palma de Mallorca : H. Son Llatzer Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Palma de Mallorca : Complejo Asistencial Son Dureta Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Palma de Mallorca : Hospital Son Llàtzer Updated
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
Pamplona :
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
Pamplona : Hospital Virgen del Camino Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Pamplona : Clínica Universitaria de Navarra Updated
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
Sabadell : Corporació Sanitaria Parc Taulí